Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Poll results: Will you use biosimilars in your ophthalmic practice?
Results from our recent poll indicate that many ophthalmologists (63%) plan to use biosimilars in their clinical practice.
Ophthalmology Times® polled our audience with the following question from September 26, 2022 to October 10, 2022: Will you use biosimilars in your ophthalmic practice?
The poll appeared on OphthalmologyTimes.com and was promoted in our e-newsletters during this time. Results show a majority of ophthalmologists plan to use biosimilars in their practice.
37 responses were recorded, in total. Of these:
23% responded, "Yes, I plan to use biosimilars in my practice."
14% responded, "No, I do not plan to use biosimilars in my practice."
.
Related Videos
Related Content
